FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Synvista Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Synvista Therapeutics, Inc. (SYNI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSYNI
SYNI
Synvista Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SYNI
Home🔹Stocks🔹Synvista Therapeutics, Inc.

Synvista Therapeutics, Inc.

SYNI•OTC

Synvista Therapeutics, Inc.

SYNI•OTC
Market cap
$3
Sentiment

Your view on SYNI

Mkt Cap
$3
Sentiment
Your view
SYNI
Synvista Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SYNI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Synvista Therapeutics, Inc.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Not available
Headquarters
221 West Grand Avenue, Parsippany, US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Not available
Headquarters
221 West Grand Avenue, Parsippany, US
Description

Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company's products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy. It is also developing a diagnostic test to identify and treat patients with diabetes who are in risk of cardiovascular disease. The company, formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Montvale, New Jersey.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News